By staff writers

April 26, 2018 -- French contrast developer Guerbet has signed an agreement to acquire laboratory-stage technology developed by Occlugel for embolization microspheres.

Under the terms of the agreement, Guerbet already has made an initial payment of 3 million euros, with additional payments dependent on completion of the technology transfer and regulatory approvals.

Occlugel specializes in the R&D of microspheres used in embolization. Its technology will be used for microspheres in the vascular embolization of benign tumors, such as uterine fibroma and prostate adenoma, and the vascular chemoembolization of malignant tumors, including some liver, lung, and kidney cancers.

The technology will add to Guerbet's interventional imaging portfolio. The company also recently acquired Accurate Medical Therapeutics, a developer of microcatheters for interventional radiology.

Copyright © 2018

To read this and get access to all of the exclusive content on create a free account or sign-in now.

Member Sign In:
MemberID or Email Address:  
Do you have a password?
No, I want a free membership.
Yes, I have a password:  
Forgot your password?
Sign in using your social networking account:
Sign in using your social networking